Samsung Biologics Co Ltd (207940) — Cash Flow Quality Index
Samsung Biologics Co Ltd (207940) has a Cash Flow Quality Index of 1.25x as of September 2025. Operating cash flow of ₩619.30 Billion exceeds net income of ₩496.48 Billion, indicating high earnings quality where cash backs reported profits. Explore 207940 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Samsung Biologics Co Ltd Cash Flow Quality Index (2015–2024)
Historical Cash Flow Quality Index for Samsung Biologics Co Ltd across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 207940 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Samsung Biologics Co Ltd (2015–2024)
Year-by-year earnings quality comparison for Samsung Biologics Co Ltd. For live market cap and the full company financial profile, see how much is Samsung Biologics Co Ltd worth.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.58x | ₩1.66 Trillion | ₩1.05 Trillion | ▼ -18.7% |
| 2023 | 1.94x | ₩1.67 Trillion | ₩857.69 Billion | ▲ +40.0% |
| 2022 | 1.39x | ₩953.05 Billion | ₩686.79 Billion | ▲ +20.1% |
| 2021 | 1.16x | ₩454.60 Billion | ₩393.59 Billion | ▲ +37.7% |
| 2020 | 0.84x | ₩202.09 Billion | ₩240.97 Billion | ▲ +1575.9% |
| 2019 | 0.05x | ₩10.15 Billion | ₩202.90 Billion | ▲ +134.0% |
| 2018 | -0.15x | ₩-33.02 Billion | ₩224.11 Billion | ▼ -6.5% |
| 2015 | -0.14x | ₩-265.51 Billion | ₩1.92 Trillion | — |